Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- 3 Top-Ranked Consumer ETFs to Buy Now
- Roundtable Top Picks of the Week
- Anatomy of Success: Green Mountain Coffee
- The Mega-Rally Rolls On
- RTI: Prediction Contest: S&P 500 on Dec. 31st
- Industry Rank Analysis: Shifting Into Overdrive
- Biotechnology ETF Investing 101
- 3 Dividend Stocks at Reasonable Prices
- Options Strategies & the Zacks Rank
- AWS 5/21: The Beginning of the End for QE
- PFP 5/21: Below the Surface
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/21/2013
| Company Name | Symbol | %Change |
|---|---|---|
| EAGLE BULK S | EGLE | 7.82% |
| RADIANT LOGI | RLGT | 4.20% |
| VIPSHOP HOLD | VIPS | 4.09% |
| FEDERAL MOGU | FDML | 3.61% |
| ERICKSON AIR | EAC | 2.45% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Recently, GlaxoSmithKline ( GSK - Analyst Report ) announced that it has filed marketing applications for two influenza vaccines.
The vaccines, up for approval, include a quadrivalent influenza vaccine for the prevention of influenza caused by types A and B strains in adults and children aged 3 years and above. The company is seeking regulatory approval in both the US and the EU.
We note that just a few days ago, AstraZeneca ( AZN - Analyst Report ) had announced the US approval of FluMist Quadrivalent for the prevention of influenza caused by two type A and two type B strains. FluMist Quadrivalent marks the first approval of a four-strain influenza vaccine by the US Food and Drug Administration (FDA).
Meanwhile, Glaxo has also submitted a Biologics License Application (BLA) to the FDA for the approval of an H5N1 influenza vaccine for use in adults. The vaccine is already approved in Europe under the trade name Pumarix.
Glaxo has a strong vaccine segment which generated sales of £3.5 billion in 2011, approximately 16% of the total product sales of the company. According to Glaxo, its vaccines business is the largest in the world.
Earlier this month, Glaxo had announced that it has signed an agreement with Daiichi Sankyo ( ) to form a joint venture (JV). The JV will be called Japan Vaccine Co., Ltd. and will focus on the vaccines business in Japan. According to Glaxo and Daiichi, Japan Vaccine Co. will be the largest vaccine company in Japan.
Japan Vaccine Co. will purchase vaccines from both Glaxo and Daiichi at fixed prices (undisclosed). The companies will share the costs and profits from the new venture equally. The initial start-up cost for Japan Vaccine Co. will be 100 million yen.
The main products of Japan Vaccine Co. will include Glaxo’s Cervarix for cervical cancer and Rotarix for rotavirus gastroenteritis.
Glaxo in Neutral Lane
We currently have a Neutral recommendation on Glaxo. The stock carries a Zacks #3 Rank (Hold rating) in the short run.
While several products in the Pharmaceuticals segment are facing generic competition, the Consumer side of the business is performing well and should help drive top-line growth. Moreover, Glaxo’s diversified base and presence in different geographical areas should help support revenue growth.
Meanwhile, Glaxo’s restructuring initiative should help offset the impact of increasing generic competition in the next few years and help increase earnings at a faster pace than revenues. Share buybacks should also drive bottom-line growth.
Read the full Analyst Report on AZN
Read the full Analyst Report on GSK